Neurofibromatosis 2 Clinical Trial
Official title:
A Study Investigating the Inter- and Intra- Rater Reliability of Functional Outcome Measures in Neurofibromatosis 2
Neurofibromatosis 2 (NF2) is a rare inherited condition. Those with NF2 usually present with tumours (schwannomas) in their inner ear, or vestibular organ, with common symptoms including problems with hearing, balance, dizziness and vision. This study aims to evaluate the reliability (stability) of a range of functional standardised outcome measures in adults with NF2.
Neurofibromatosis 2 (NF2) is an inherited condition that occurs in 1 in 33,000 births;
affecting hearing, balance, dizziness and vision primarily related to tumours (schwannomas)
in the inner ear or other tumours which develop within the central nervous system. Neuropathy
may also be an issue for people with NF2.
The complications of NF2 can lead to varied difficulties with activities of daily living and
may impair quality of life. More recently, new pharmacological treatments for NF2 are being
trialed which may have the potential to dramatically influence quality of life for people
with NF2. Currently, evaluation of treatment effect in NF2 is based on a clinician's
neurological assessment and imaging. However, imaging results do not always correlate with
clinical and reported functional changes of the individual. Therefore, evaluating the effect
of interventions or treatment should include the evaluation of a person's function using
standardised outcome measures. The findings from this study will improve the care of people
with NF2 by ensuring that we are able to measure functional changes in a person with NF2 with
greater confidence, meaning that we can start, continue or cease treatments based on the
holistic picture of an individual.
The world confederation of physiotherapists (WCPT) stipulates that standardised outcome
measures (SOM) are used to provide a quantitative measure of capability, and to evaluate the
impact of treatment on function. There are a wide range of SOM's that evaluate function so a
SOM is chosen by the clinician based on the patient's presenting functional difficulty and
the scientific credibility of the SOM. Scientific credibility (robustness) is based on
scientific properties of the SOM i.e. how stable the SOM is (reliability) and whether it
assesses what it is intending to assess (validity). It is important to evaluate each SOM
within the target population as variability within that condition, strongly influences the
SOM's reliability and validity (de Vel 2011).
At present, functional SOM's have limited scientific and subsequent clinical credibility when
used in people with NF2 because their scientific properties have not yet been evaluated
within this patient group which means that if they are used clinically or within research,
there is an inherent element of doubt when interpreting the SOM's results. The objective of
this research team is to create a core set of functional SOM's which have undergone rigorous
scientific evaluation so that they can be used in the future for clinical practice and for
research purposes in adults with NF2.
This study primarily aims to evaluate three commonly used SOM's for reliability in adults
with NF2 (over 16 years of age). The measures chosen for evaluation are the nine hole peg
test, the four square step test and the modified clinical test of sensory integration and
balance (mCTSIB). Interrater reliability (the test result remains the same when reviewed by
different people) and intrarater reliability (the test result remains stable when reviewed
twice by the same tester) will be evaluated. From this data, we will be able to calculate the
standard error of measurement an additional important scientific characteristics of SOM
evaluation. A secondary objective is to correlate SOM objective markers with a subjective
disease specific quality of life measure (NFTI-QOL) and self-reported falls rate and near
misses. We will also collect data on dynamic visual acuity in this patient group.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00973739 -
Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
|
Phase 2 | |
Completed |
NCT00030043 -
An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors
|
Phase 1 | |
Recruiting |
NCT05685836 -
89Zr-Bevacizumab PET/CT Imaging in NF2 Patients
|
||
Completed |
NCT00004437 -
Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2
|
Phase 2 | |
Recruiting |
NCT03406208 -
Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing
|
N/A | |
Suspended |
NCT03095248 -
Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
|
Phase 2 | |
Completed |
NCT02298270 -
Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype
|
N/A | |
Recruiting |
NCT01885767 -
Neurofibromatosis (NF) Registry Portal
|
||
Completed |
NCT00863122 -
Concentration and Activity of Lapatinib in Vestibular Schwannomas
|
Early Phase 1 | |
Recruiting |
NCT03079999 -
Study of Aspirin in Patients With Vestibular Schwannoma
|
Phase 2 | |
Terminated |
NCT00911248 -
PTC299 for Treatment of Neurofibromatosis Type 2
|
Phase 2 | |
Completed |
NCT02811718 -
Resiliency Training for Patients With NF2 Via Videoconferencing With Skype
|
N/A | |
Enrolling by invitation |
NCT04890132 -
Vestibular Precision: Physiology & Pathophysiology
|
N/A | |
Completed |
NCT01490476 -
Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients
|
Phase 2 | |
Active, not recruiting |
NCT00004483 -
NF2 Natural History Consortium
|
N/A | |
Recruiting |
NCT03893643 -
Cutaneous and Mucosal Manifestations of Neurofribromatosis Type 2 in Children Under 15
|
||
Active, not recruiting |
NCT04283669 -
Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
|
Phase 2 | |
Completed |
NCT02831257 -
AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
|
Phase 2 |